Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher's NSCLC Companion Dx Covered by Regence BCBS

UPDATE: The story had incorrectly stated that the test was FDA approved as a companion diagnostic to identify patients with ALK mutations who may respond to the cancer drug Xalkori. We regret the error.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific today said its Oncomine Dx Target Test has received a positive coverage decision from Regence Blue Cross Blue Shield.

As a result, the insurer will cover the test for its members with non-small cell lung cancer in Oregon, Idaho, Utah, and certain counties in Washington.

The next-generation sequencing-based companion diagnostic, which simultaneously evaluates 23 genes clinically associated with NSCLC, allows physicians to match patients to therapies, which have been approved by the US Food and Drug Administration, in days instead of weeks, Thermo Fisher said.

The FDA approved the panel in June to predict which patients with EGFR mutations, ROS1 rearrangements, and BRAF mutations are likely to derive benefit from Iressa (gefitinib), Xalkori (crizotinib), and the Mekinist (trametinib)/Tafinlar (dabrafenib) combo, respectively. In August, the test received a proprietary laboratory analyses code from the American Medical Association, Thermo Fisher said. 

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.